A one-step, one-tube real-time RT-PCR based assay with an automated analysis for detection of SARS-CoV-2

Bhasker Dharavath a,e,1, Neelima Yadava a,e,1, Sanket Desai a,e,1, Roma Sunder a, Rohit Mishra a, Madhura Ketkar b,e, Prasanna Bhanse c,e, Anurodh Gupta c,e, Archana Kumari Redhu a, Nikhil Patkar c,e, Shilpee Dutt b,e, Sudeep Gupta b,e, Amit Dutt a,e,f,*

a Integrated Cancer Genomics Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Kharghar, Navi Mumbai, Maharashtra, 410210, India
b Shilpee Dutt Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Kharghar, Navi Mumbai, Maharashtra, 410210, India
c Haematopathology Laboratory, Advanced Centre for Treatment, Research, and Education in Cancer, Kharghar, Navi Mumbai, Maharashtra, 410210, India
d Department of Medical Oncology, Advanced Centre for Treatment, Research, and Education in Cancer, Kharghar, Navi Mumbai, Maharashtra, 410210, India
e Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, Maharashtra, 400094, India
f Adjunct Faculty, Institute of Advanced Virology, Kerala State Council for Science, Technology and Environment, Govt of Kerala, Thonnakkal, Kerala, 695317, India

ARTICLE INFO

Keywords: Infectious disease
Microbial genomics
Genomics
Molecular biology
Virology
Diagnoses
SARS-CoV-2
Real-time RT-PCR
COVID-19 detection assay
COVID-qPCR analyzer
Graphical user interface (GUI)

ABSTRACT

Early diagnosis of SARS-CoV-2 infected patients is essential to control the dynamics of the COVID-19 pandemic. We develop a rapid and accurate one-step multiplex TaqMan probe-based real-time RT-PCR assay, along with a computational tool to systematically analyse the data. Our assay could detect to a limit of 15 copies of SARS-CoV-2 transcripts—a based on experiments performed by spiking total human RNA with in vitro synthesized viral transcripts. The assay was evaluated by performing 184 validations for the SARS-CoV-2 Nucleocapsid gene and human RNase P as an internal control reference gene with dilutions ranging from 1-100 ng for human RNA on a cohort of 26 clinical samples. 5 of 26 patients were confirmed to be infected with SARS-CoV-2, while 21 tested negative, consistent with the standards. The accuracy of the assay was found to be 100% sensitive and 100% specific based on the 26 clinical samples that need to be further verified using a large number of clinical samples. In summary, we present a rapid, easy to implement real-time PCR based assay with automated analysis using a novel COVID qPCR Analyzer tool with graphical user interface (GUI) to analyze the raw qRT-PCR data in an unbiased manner at a cost of under $3 per reaction and turnaround time of less than 2h, to enable in-house SARS-CoV-2 testing across laboratories.

1. Introduction

Diagnostics can play an important role in the containment of COVID-19, enabling rapid implementation of control measures that limit the spread through case identification, isolation, and contact tracing (i.e., identifying people that may have come in contact with an infected patient). The COVID-19 causative agent is a novel Coronavirus belonging to genus beta-coronavirus of Coronaviridae family having shown genome sequence similarities of about 80%, 50% and ~90% with the previously reported SARS-CoV, MERS-CoV and SARS-like bat-CoV respectively [1, 2, 3, 4]. The novel coronavirus, termed as SARS-CoV-2 by the International Committee on Taxonomy of Viruses (ICTV) has created havoc around the globe causing at least 347,011 deaths out of 5,526,224 confirmed cases across 215 countries as of 26th May 2020 [5].

The symptoms expressed by COVID-19 patients- fever (89%), cough (68%), fatigue (38%), sputum production (34%), and shortness of breath (19%) –are nonspecific and cannot be used for an accurate diagnosis [6]. Molecular techniques, on the other hand, are more suitable for accurate diagnoses because they can target and identify specific pathogens. The most commonly used targets for primer/probe development in case of SARS-CoV-2 are from conserved viral genome including ORF1ab gene, RdRP gene (RNA dependent RNA polymerase), N gene (Nucleopcapsid) and E gene (Envelope) [2, 7, 8]. Apart from conventional RT-PCR and quantitative RT-PCR, various studies have reported modifications like nested rRT-PCR, RT-PCR with locked

* Corresponding author.
E-mail address: adutt@actrec.gov.in (A. Dutt).
1 Equal contribution.
nucleic acid probes and RT-Loop Mediated isothermal Amplification (RT-LAMP) for detection of Coronaviruses [9, 10, 11], e.g. the RT-LAMP method for detection of MERS-CoV with sensitivity as high as ~3.4 copies of RNA/reaction, a microarray-based methodology to detect strains of coronaviruses simultaneously, CRISPR effector Cas13 based SHERLOCK for viral RNA detection with isothermal amplification, and more recently for the COVID-19 [9, 12, 13, 14]. Despite such varied efforts to increase sensitivity and specificity of the viral diagnostics, there is still an unmet need for user-friendly and cost-effective detection method to combat the ongoing catastrophe created by SARS-CoV-2.

Analyzing the human coronavirus genome sequences, we have designed a combination detection method involving a novel primer targeting SARS-CoV-2 Nucleocapsid N gene sequence with two primer pairs each probing to another non-overlapping region of SARS-CoV-2 Nucleocapsid N gene and ORF1ab gene respectively. Using primers targeting SARS-CoV-2 specific regions, we present a comparative account of a DNA-binding dye SYBR Green I and sequence-specific dually fluorophore-labelled hydrolysis (TaqMan) probe-based qRT-PCR to help develop a one-step, one tube multiplex real-time RT-PCR reaction based assay for simple, reliable and rapid detection of the COVID-19 virus. For quantitative assessment of the data generated from the RT-PCR assay, we developed COVID qPCR Analyzer, a graphical user interface (GUI) based tool for reproducible downstream analysis and automated report generation of the analysed samples.

2. Materials and methods

2.1. Patient samples

Validation of the one-step, one-tube, multiplex probe-based real-time PCR assay presented in this study was performed on total RNA derived from swabs obtained from 26 patients who were referred for COVID-19 testing at the Department of Haematopathology Laboratory, ACTREC-TMC, as a routine service, which is a Government approved and authorized testing laboratory for COVID-19 by the Indian Council of Medical Research. This was part of standard care; therefore, no IRB approval was obtained. All patient samples obtained were anonymized and no patient specific characteristics including the age, gender, or any clinicopathological features of the patients were accessed.

2.2. SARS-CoV-2 specific sequence selection, primer and probe design

Genome sequences of 93 SARS-CoV-2, 6 human-specific SARS viruses and 27,399 related SARS/SARS-like viruses were downloaded from NCBI-Virus database [15]. These included the 56 reference genomes of the Coronavirus family of which the coding regions were also separately downloaded for analysis. Multiple sequence alignment was performed using the MAFFT tool [16] to identify conserved regions among the genes and Nucleotide BLAST was used for sequence comparisons. Three target regions for detection were selected using the Indian isolate of the SARS-CoV-2 genome (GenBank reference: 29854). Primers were designed using the Primer3plus [17] for the Nucleocapsid gene region (N1). The other two regions from the Nucleocapsid gene and ORF1ab gene (N2, N3) respectively were selected from literature (Supplementary Table S1) [18]. Dual-labelled TaqMan probes (Eurofins Scientific India Pvt Ltd, Bangalore) were designed for N1, N2 and C1 (Supplementary Table S2) using PrimerQuest tool (https://eu.idtdna.com/pages/tools/primerquest). In silico validation was performed by subjecting the templates generated from the selected regions/primer pairs to local blast (Nucleotide BLAST algorithm) based alignment against the available complete SARS-CoV-2 genome isolates and other SARS viruses having a human and non-human host.

2.3. Cloning and viral template synthesis

SARS-CoV-2 positive template control for SARS-CoV-2 Nucleocapsid gene (N1 and N2) and ORF1ab gene (N3) were generated in two-steps. The single-stranded synthetic DNA fragments (Supplementary Table S3) were concatenated and amplified by overlap extension PCR (OE-PCR) [19] for cloning in pJET.2/blunt cloning vector (Clone/JET PCR Cloning Kit, Cat. K1232) as per manufacturer’s instruction. N1, N2 and N3 synthetic fragment cloned plasmids were linearized at 3’ end using XbaI enzyme (NEB, Cat. R0145S). In Vitro Transcription (IVT) reaction was set up using T7 RNA polymerase (Promega, Cat. 207B) with each gel-purified plasmid and incubated at 37 °C for 2 h as described previously [20]. The resultant mixture was subjected to DNase I treatment (rDNase I DNA-free kit, Cat. No. 2224G, Invitrogen BioServices India Pvt. Ltd.) for digestion of left-over plasmid DNA and purification was confirmed by denaturing RNA agarose gel electrophoresis.

2.4. cDNA synthesis and qRT-PCR assay

For each IVT synthesized N1, N2 and N3 transcripts, cDNA was synthesized using PrimeScript cDNA synthesis kit (Cat. RR037A, Takara) with range of concentrations of IVT RNA (1pg, 10pg, 100pg and 1000pg) and total human RNA (50ng) as per manufacturer’s protocol, qPCR with each synthetic viral DNA/IVT RNA fragment with or without either human cDNA or genomic DNA (10ng) as template was performed using SYBR Green Master Mix (Kapa SYBR Fast Universal qPCR kit, Cat. KK4601). RNase P (C1) was used as an internal reference control. Each 20ul reaction contained 10ul 2X SYBR green master mix (Kapa SYBR Fast Universal qPCR kit, Cat No. KK4601), 1ul of forward and reverse primers each along with either 1ul of human cDNA/gDNA, 1ul of synthetic viral DNA template and 6ul of nuclelease-free water or 8ul of cDNA prepared from viral IVT RNA in the reaction mixture.

2.5. One-step qRT-PCR assay

Dual labelled TaqMan probes with 5’-6-FAM fluorescent dye and 3’-BHQ-1 quencher for two SARS-CoV-2 target sequences N1 and N2 were used for the detection of viral RNA. For internal reference control, a pair of primers and TaqMan probe for RNase P (C1), labelled with 5’-HEX fluorescent dye and 3’-BHQ-1 quencher were used. Quantitative RT-PCR was performed with a range of concentrations of SARS-CoV-2 synthetic DNA/RNA/both (1pg, 10pg, 100pg and 1000pg) along with human genomic DNA (10ng)/total RNA (50ng)/both as template using KqCqStart One-Step Probe RT-qPCR ReadyMix (Cat. KCQ507, Merck Life Science Private Limited). Fluorescent dye program was selected as 6-FAM for TaqMan probes, N1 and N2, and VIC was selected for TaqMan probe, C1. For both the probes, no quencher option was selected in the program.

2.6. One-step, One-tube Multiplex qRT-PCR assay

For multiplexing qRT-PCR with TaqMan probes, each reaction mixture was prepared with a range of concentrations (1 pg, 10 pg, 100 pg and 1000 pg) for SARS-CoV-2 synthetic DNA/IVT RNA. Thermocycler conditions and fluorescence dye settings were selected similar to One-step TaqMan RT-PCR in QuantStudio 5 Real-Time PCR system (Applied BioSystems, Cat no. A34322). In addition to the test samples, a positive control, negative control and no template control well make a set of reference sample for each assay. The positive control reference includes SARS-CoV-2 positive template control for SARS-CoV-2 synthetic DNA/RNA/both (1pg, 10pg, 100pg and 1000pg) and 1ul of synthetic viral DNA template and 6ul of nuclelease-free water or 8ul of cDNA prepared from viral IVT RNA in the reaction mixture.

2.7. Development of COVID qPCR analyzer tool

The tool is designed to process the qRT-PCR raw data (XLS format) to generate a report stating the positivity of the sample. The Ct values for
individual wells on the plate (assigned to specific samples) are extracted for the viral test and control probe. Firstly, the tool checks if the Ct value of positive control well, is less than the threshold for the test probe and has undetermined Ct values for both test and control probe for the specified no template control well. In brief, the following algorithm is used to call a sample as COVID-19 positive/negative or to assess if the validity of the PCR run; a) a sample is “positive” in case the test gene probe is less than the Ct threshold (irrespective of control probe value), b) a sample is called “negative”, if Ct value for test greater than a threshold and of that of control probe is less than the Ct threshold set. In case the Ct value for the test and control probe is undetermined or greater than the threshold, the run for the sample is considered “invalid”. Implementation of the tool, including the graphical user interface has been done using R programming (www.r-project.org/) and gWidgets2 (https://github.com/jverzani/gWidgets2). The basic script to parse and extract data from qRT-PCR raw data is adopted from the project (https://github.com/TaylorMatte/Quant6-Covid_Analysis), of a recently published study [21]. The COVID qPCR Analyzer tool (instruction manual provided as Supplementary File1) along with the test data and output files is freely available for download at www.actrec.gov.in/pi-webpages/AmitDutt/Covid/Analyzer.html.

3. Results

3.1. Generation of SARS-CoV-2 synthetic viral template

Comparative sequence analysis was performed to understand the evolutionary conservation within the SARS-CoV-2 genomes and divergence among the genomes across the various members of Coronaviridae family and other human infecting SARS viruses. We selected a region of the SARS-CoV-2 Nucleocapsid gene, which was conserved across all the available CoV-2 isolate genomes (RefSeq ID NC_045512.2: 28917-29134). We additionally selected two regions reported earlier in the literature [18]. Multiple sequence alignment between the three templates (hereafter called N1, N2 and N3) and respective genomic regions in all SARS-CoV-2 isolates and other human infecting SARS viruses has been shown in Figure 1. Basic criteria for selection of these three regions was conservation across all the available SARS-CoV-2 genomes and non-conservation between other human SARS viruses. Primers for Overlap extension PCR and 3 specific primer pairs for real time PCR were designed for N1, N2 and N3 regions to amplify unique N1 (209bp), N2 (110bp) and N3 (132bp) fragments as SARS-CoV-2 synthetic DNA representing the Nucleocapsid gene and ORF1ab gene respectively (Figure 1). Overlap extension PCR with Q5 DNA polymerase was used to amplify each of these concatenated oligonucleotide fragments. The amplified products were cloned into pJET1.2/Blunt vector and confirmed on an agarose gel after restriction digestion with a combination of enzymes PstI, HindIII and Xbal. The viral synthetic DNA templates were transcribed in vitro using T7 DNA dependent RNA polymerase after linearizing the plasmid vector with Xbal. RNA agarose gel electrophoresis for the IVT RNAs confirmed the sizes and purity of transcripts in both DNase I treated and untreated samples (Supplementary Figure S1).

3.2. SARS-CoV-2 detection by quantitative real-time PCR

To mimic the complexity of a clinical sample, serial dilutions of the in vitro transcribed RNA and viral synthetic DNA (see methods) were used as a template for qRT-PCR/qPCR along with 10ng human cDNA, or 10ng human gDNA, or 50ng human total RNA as background based on SYBR-Green I fluorescence. The Ct values for all test primers targeting SARS-CoV-2 Nucleocapsid gene (N1 and N2) and ORF1ab gene (N3) showed decreasing trend with increasing concentration (1pg, 10pg, 100pg and 1000pg) of the synthetic DNA fragments at a minimal amount of 1pg for both the synthetic DNA and RNA viral templates, while the Ct value for RNase P (C1), included as an internal reference control, remained comparable across indicating the constant amount of carrier DNA and RNA. Importantly, the Ct value for no template control wells remained undetermined across all the experiments (Figure 2). The melting curve genotyping analysis for all the primer pairs, except N3 that was excluded from further analysis, showed a single peak suggesting the absence of any non-specific amplification products (Figure 2). Thus, Ct value less than or equal to 30, of products N1, N2, and C1 indicate positive signal for SARS-CoV-2 with the limit of detection at 1pg for synthetic SARS-CoV-2 suggesting high sensitivity of primers to detect small traces of SARS-CoV-2. Given that dually fluorophore-labelled hydrolysis TaqMan probes offer an alternative approach to the problem of specificity, we compared the findings obtained using SYBR-Green chemistry by designing TaqMan probes for the detection of the two Nucleocapsid gene (N1 and N2) with 6-
FAM/BHQ-1 dual labelled fluorophore and quencher, while the control probe targeting the human RNase P gene (C1) was tagged with HEX/BHQ-1 dye. Using the in vitro synthesized SARS-CoV-2 synthetic N1 and N2 transcripts and DNA fragments serial dilutions of 1pg, 10pg, 100pg and 1000pg were prepared as a template in the background of human total RNA (50ng) or genomic DNA (10 ng) or both. Similar to the findings based on SYBR-Green I dye, the TaqMan qRT-PCR results showed a decrease in Ct value for N1 and N2 with increasing concentration of SARS-CoV-2 in vitro transcribed RNA or synthetic DNA or both (Figure 3) that could similarly detect SARS-CoV-2 RNA as low as 1pg in a sample, in the background of human total RNA or human genomic DNA or both suggesting comparable specificity of the N1 and N2 primers and probe to detect SARS-CoV-2 RNA in the sample (Figure 3). The Ct value for C1 remained constant,
With the increasing need for more cost-effective SARS-CoV-2 detection, it is of paramount relevance to detect multiple reference target and internal reference control genes in the same tube, without compromising specificity of single amplicon was represented in the respective amplification curve indicating 6-FAM/HEX fluorescence signal emitted by dual labelled probes in multiplex PCR.

3.3. COVID qPCR analyzer, an automated tool to quantitatively analyze and interpret the qRT-PCR assay

To minimize variability and automate the qRT-PCR downstream analysis of multiple samples in the same run, we further developed a GUI based automated in silico analytical tool, COVID qPCR Analyzer (www.actrec.gov.in/pi-webpages/AmitDutt/Covid/Analyzer.html), to detect the virus in an unambiguous and reproducible manner. The tool poses a minimal requirement of third-party tools and is compatible with output obtained from any real-time PCR machine – in a platform-independent manner, ensuring its universal application and adaptability across laboratories. The COVID qPCR Analyzer allows the flexibility to adjust the threshold of Ct value to fall within the exponential phase of the fluorescence curves and above any background signal based on the reference sample. A positive result is indicated with a Ct value of less than the defined threshold with simultaneous detection for two regions of SARS-CoV-2 Nucleocapsid gene, irrespective of the Ct value determined for the internal reference control gene RNase P. A negative result is indicated with a Ct value of higher than the threshold for the two regions of SARS-CoV-2 Nucleocapsid gene, with a Ct value below the threshold for the internal reference control gene RNase P. In case the Ct value of the SARS-CoV-2 Nucleocapsid gene and the internal reference control gene RNase P exceeds the threshold or remains undetermined, indicate an inconclusive outcome with a requirement to repeat the test (Table 1).

3.4. Clinical validation and accuracy of the one-step, one tube, multiplex probe-based qRT-PCR assay

A total of 26 clinical samples were investigated with two primer sets for SARS-CoV-2 Nucleocapsid gene (N1 and N2) and a primer set for human RNase P gene (C1) by real-time RT-PCR. The data was analysed using COVID qPCR Analyzer, wherein a positive result was indicated with a Ct value equal to or less than 30; negative result with a Ct value of higher than 30 for the two regions of SARS-CoV-2 Nucleocapsid gene and internal reference control gene RNase P. 5 of 26 patient samples were confirmed to be infected with SARS-CoV-2, while 21 tested negative (Table 2), consistent with the gold standard outcomes obtained using commercial kits. Thus, the sensitivity was 100% and specificity was 100%. A total of 115 validations were performed for SARS-CoV-2 Nucleocapsid genes and 69 validations for the human RNase P gene (C1) by real-time RT-PCR with several dilutions ranging from 1-100 ng of the clinical samples. In addition, the accuracy of the one-step, one-tube, a multiplex probe-based real-time PCR assay was determined with the

| N1 - N2 | C1 | Result              |
|--------|----|---------------------|
| +      | +  | SARS-CoV-2 detected |
| +      | −  | SARS-CoV-2 detected |
| −      | +  | SARS-CoV-2 not detected |
| −      | −  | Inconclusive result |
| −      | +  | Ct value equal to or less than 30 |
| −      | −  | Ct value more than 30 |
vitro synthesized SARS-CoV-2 RNA synthetic transcripts in the background of human total RNA. The real-time RT-PCR reactions performed detected Ct value with the limiting amount of 500pg of the total template with SYBR Green I dye and 50pg with the TaqMan probe-based methodology, below which Ct values couldn't be determined. Using the graphical interface of the NEBiocalculator, the limit of detection (LoD) was determined to be 150 and 15 RNA copies/reaction for the SYBR Green dye-based and TaqMan probe-based methodologies (https://nebiocalculator.neb.com/#/ssrnaamt).

4. Discussion

We describe a comparative account of qRT-PCR based detection of SARS-CoV-2 using SYBR Green I and Taqman probes. Although SYBR Green-based qRT-PCR protocol is comparatively economical, the non-specific binding of the dye to DNA resulted in low specificity and sensitivity with limit of detectability of 150 copies of viral RNA molecules/reaction, whereas TaqMan probe-based protocol could detect as low as 15 copies of viral RNA molecules/reaction suggesting higher sensitivity. Moreover, consistent with the guidelines by WHO and for the reliability of results wherein at least two genomic targets are required for diagnostic test [8], the TaqMan probe based assay allows to multiplex the two viral specific target probes along with the human control probe, labelled by different fluorophores, in the same tube as a one-step, one-tube multiplex probe-based qRT-PCR reaction.

Furthermore, in comparison to 13 different SARS-CoV-2 detection kits (6 based on qRT-PCR; 5 based on RT-LAMP; and 2 based on CRISPR-Cas12-RT-LAMP) reported in the literature (Supplementary Table S4) [4, 5, 13, 14, 23, 24, 25, 26, 27, 28, 29, 30, 31], the one-step, one-tube, multiplex probe-based real-time PCR assay derives its strength from the fact that it can be offered at the point-of-care testing for the detection of SARS-CoV-2 by using dual TaqMan test probes, both labelled with 6-FAM/ BHQ-1, targeting unique regions of the SARS-CoV-2 Nucleocapsid gene along with an internal reference control gene RNase P probe labeled with HEX-1/BHQ-1, simultaneously. Along with the RNA extraction process, the qRT-PCR and analysis can be completed in less than 2h that can be easily compiled and delivered in a form of an automated report generated using COVID qPCR Analyzer, a GUI based in silico analytical tool, in an unambiguous and reproducible manner, making it highly cost-effective. Moreover, the GUI allows the user to set an adjustable threshold Ct value based on the reference samples correcting for the individual bias that may vary between runs due to varying template quality and ensures the universal applicability of the automated analyzer tool, based on single target probe with subsequent provisions for customization to adapt for multiple target test probes.

A major shortcoming of the one-step, one-tube, multiplex probe-based real-time PCR assay is that the primer sequences designed for the two regions within the SARS-CoV-2 Nucleocapsid gene is based on the alignment of in 93 SARS-CoV-2 genomes isolates compared against 27,399 human-specific SARS/SARS-like genomes obtained from NCBI-virus database [15]. However, with the pandemic status of COVID-19, the accuracy of the one-step, one-tube, multiplex probe-based real-time PCR assay may be affected by the variations arising within the primers to amplify the target genes and affecting the binding of the TaqMan probes designed within the target regions. A complementary approach with the availability of whole genome sequencing of the evolving SARS-CoV-2 sequence would help to address the variability and update the assay described here. Secondly, the real time-RT PCR assay involves intensive laboratory steps with a requirement of skilled manpower to perform the assay that requires a modern molecular laboratory infrastructure and an expensive instrument. Thirdly, the accuracy of the one-step, one-tube, multiplex probe-based real-time PCR assay needs to be further verified and evaluated using a large number of clinical samples. Thus, there remains an unmet need to simplify the detection at the point of care in a portable manner. Lastly, as a general shortcoming of the real time-RT PCR based negative outcome of SARS-CoV-2 test does not necessarily rule out infection in the course of an individual patient's disease.

In conclusion, the one-step, one-tube, multiplex probe-based real-time PCR assay with automated qPCR analyzer described in this study demonstrates high diagnostic sensitivity and specificity using clinical samples to detect the presence of SARS-CoV-2. Given the lack of effective therapeutic intervention available such as vaccines or treatments, early diagnosis of COVID-19 is the most crucial alternative to reduce SARS-CoV-2 transmission by identifying and isolating infected individual to flatten the spread of the COVID-19 virus. The assay may be further evaluated across multicentre as prospective studies in the context of clinical management during the prevailing COVID-19 outbreak and may be of high significance for different laboratories to set a diagnostic facility in an economical way. An effective and validated one-step, one-tube, multiplex probe-based real-time PCR assay described can be easily adapted by the community and would help further improve our understanding of the current estimates of COVID-19 case-fatality rates that are most likely inflated in the current scenario due to the preferential availability of data from countries with better diagnostic capabilities, underscoring the significance of universal availability of accurate diagnostic testing methodologies during the COVID-19 pandemic.

Declarations

Author contribution statement

B. Dharavath and N. Yadav: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

S. Desai and A. Dutt: Conceived and designed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

R. Sunder, P. Bhanshe, A. Gupta and A. Redhu: Performed the experiments; Analyzed and interpreted the data.

R. Mishra, N. Patkar, S. Dutt and S. Gupta: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.

M. Ketkar: Analyzed and interpreted the data; Wrote the paper.

Funding statement

A. Dutt was supported by Advanced Centre for Treatment, Research and Education in Cancer.

Competing interest statement

The authors declare no conflict of interest.

Additional information

Supplementary content related to this article has been published online at https://doi.org/10.1016/j.heliyon.2020.e04405.
Acknowledgements

All members of the Dutt laboratory for critically reading the manuscript. Dr. Narayan Rao, BARC and Dr. Ujawala Warawdekar, ACTREC for sharing reagents. Mr. Sujeet Kumar, Eurofins Scientific India Pvt Ltd, Bangalore for expedited synthesis of the probes. Ms. Thushara Pillai, Merck Life Science Private Limited and Mr. Sameer Patil, Invitrogen BioServices India Pvt Ltd. Thermo Fisher Scientific for expedited processing of the reagents. Ms. Seema Menon and Mr. Vishal Gaikwad, BlueDart Express Limited, Mumbai for an expedited delivery while the country was under lockdown!

References

[1] R. Lu, et al., Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet 395 (10244) (2020) 565-574.
[2] N. Zhu, et al., A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med. 382 (8) (2020) 727–733.
[3] B. Udagama, et al., Diagnosing COVID-19: the disease and tools for detection, ACS Nano (2020).
[4] D.K.W. Che, et al., Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia, Clin. Chem. 66 (4) (2020) 549-555.
[5] C. Yan, et al., Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay, Clin. Microbiol. Infect. (2020).
[6] W.J. Guan, et al., Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med. (2020).
[7] J.Y. Noh, et al., Simultaneous detection of severe acute respiratory syndrome, Middle East respiratory syndrome, and related bat coronaviruses by real-time reverse transcription PCR, Arch. Virol. 162 (6) (2017) 1617–1623.
[8] World Health, O., Laboratory Testing for Coronavirus Disease (COVID-19) in Suspected Human Cases: Interim Guidance, 19 March 2020, World Health Organization, Geneva, 2020.
[9] K. Shirato, et al., Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP), Virol. J. 11 (2014) 139.
[10] J.F. Chan, et al., Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic coronaviruses, J. Clin. Microbiol. 53 (8) (2015) 2722–2726.
[11] S.S. Jiang, et al., Sensitive and quantitative detection of severe acute respiratory syndrome coronavirus infection by real-time nested polymerase chain reaction, Clin. Infect. Dis. 38 (2) (2004) 293–296.
[12] Q. Chen, et al., Comprehensive detection and identification of seven animal coronaviruses and human respiratory coronavirus 229E with a microarray hybridization assay, Intervirology 53 (2) (2010) 95–104.
[13] C.A. Freije, et al., Programmable inhibition and detection of RNA viruses using Cas13, Mol. Cell 76 (5) (2019) 826–837 e11.
[14] Feng Zhang, O.O. Abudayyeh, Jonathan Gootenberg, A Protocol for Detection of COVID-19 Using CRISPR Diagnostics, 2020.
[15] E.L. Hatcher, et al., Virus Variation Resource – improved response to emergent viral outbreaks, Nucleic Acids Res. 45 (D1) (2017) D482–D496.
[16] K. Kato, D.M. Standley, MAFFT multiple sequence alignment software version 7: improvements in performance and usability, Mol. Biol. Evol. 30 (4) (2013) 772–780.
[17] A. Unteragner, et al., Primer3Plus, an enhanced web interface to Primer3, Nucleic Acids Res. 35 (2007) W71–W74 (Web Server).
[18] R. Sah, et al., Complete genome sequence of a 2019 novel coronavirus (SARS-CoV-2) strain isolated in Nepal, Microbiol. Resour. Announc. 9 (11) (2020) e00169-20.
[19] R. Higuchi, B. Krummel, R. Saiki, A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions, Nucleic Acids Res. 16 (15) (1988) 7351–7367.
[20] Z. Xing, C. Lin, L. Yang, LncRNA pulldown combined with mass spectrometry to identify the novel LncRNA-associated proteins, Methods Mol. Biol. 1402 (2016) 1–9.
[21] K. Vanmyutel, A. Mithal, R.M. Giadone, A.K. Yeung, T.M. Matte, T.W. Dowrey, R.B. Wereder, G.J. Miller, N.S. Miller, C.D. Andry, G.J. Murphy, Rapid implementation of a SARS-CoV-2 diagnostic qRT-PCR test with emergency use authorization at a large academic safety-net hospital, Med 3 (2020).
[22] M. Tajadini, M. Panjehpour, S. Javanmard, Comparison of SYBR Green and TaqMan methods in quantitative real-time polymerase chain reaction analysis of four adenovirus receptor subtypes, Adv. Biomed. Res. 3 (1) (2014) 85.
[23] V.M. Gorman, et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill. 25 (3) (2020).
[24] Protocol: Real-Time RT-PCR Assays for the Detection of SARS-CoV-2, WHO.
[25] CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
[26] C.C. Yip, et al., Development of a novel, genome subtraction-derived, SARS-CoV-2-specific COVID-19-nsp2 real-time RT-PCR assay and its evaluation using clinical specimens, Int. J. Mol. Sci. 21 (7) (2020).
[27] J.F.-W. Chan, et al., Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens, J. Clin. Microbiol. 58 (5) (2020) e00310-e00320.
[28] J.P. Broughton, et al., Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2, Emerg. Microb. Infect. 9 (1) (2020) 998–1007.
[29] G.S. Park, et al., Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2, J. Mol. Diagn. (2020).
[30] R. Lu, et al., A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2, Int. J. Mol. Sci. 21 (8) (2020).
[31] J.P. Broughton, et al., CRISPR-Cas13-based detection of SARS-CoV-2, Nat. Biotechnol. (2020).
[32] K.G. Andersen, et al., The proximal origin of SARS-CoV-2, Nat. Med. 26 (4) (2020) 450–452.